Related Experiment Video

Updated: May 9, 2026

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

Synthetic lethal targeting of PTEN-deficient cancer cells using selective disruption of polynucleotide

Todd R Mereniuk1, Mohamed A M El Gendy, Ana M Mendes-Pereira

  • 1Corresponding Author: Michael Weinfeld, Cross Cancer Institute, University of Alberta, 11560 University Ave, Edmonton, AB, Canada, T6G 1Z2. michael.weinfeld@albertahealthservices.ca.

Molecular Cancer Therapeutics
|July 26, 2013
PubMed

Insights

Synthetic lethality between polynucleotide kinase/phosphatase (PNKP) and phosphatase and tensin homolog deleted on chromosome 10 (PTEN) was identified. Inhibiting PNKP in PTEN-deficient cancers may enhance radiotherapy effectiveness.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • DNA Repair Mechanisms

Background:

  • The DNA repair protein polynucleotide kinase/phosphatase (PNKP) plays a crucial role in maintaining genomic stability.
  • The tumor suppressor phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is frequently lost in various cancers.
  • Identifying synthetic lethal interactions can reveal novel therapeutic strategies for cancer treatment.

Purpose of the Study:

  • To investigate the synthetic lethal interaction between PNKP and PTEN.
  • To explore the therapeutic potential of targeting PNKP in PTEN-deficient tumors.

Main Methods:

  • siRNA screening to identify synthetic lethal partners of PNKP.
  • Cell line experiments (PC3, HCT116) to confirm synthetic lethality.
  • Apoptosis assays and DNA double-strand break analysis.
  • Complementation assays with mutated PTEN cDNAs.
  • Radiosensitivity assays in PTEN-deficient cells.

Main Results:

  • A synthetic lethal partnership between PNKP and PTEN was confirmed across multiple cell lines.
  • Codepletion of PTEN and PNKP induces apoptosis.
  • PTEN loss in HCT116 cells leads to increased DNA double-strand breaks upon PNKP inhibition.
  • PTEN's cytoplasmic lipid phosphatase activity is critical for preventing toxicity from PNKP inhibition.
  • PNKP inhibition enhances radiosensitivity in PTEN-deficient cells.

Conclusions:

  • The PNKP/PTEN interaction represents a novel synthetic lethal vulnerability.
  • Targeting PNKP in PTEN-deficient cancers, potentially through a "synthetic sickness" approach, could enhance radiotherapy efficacy.
  • This strategy offers a promising avenue for treating PTEN-deficient tumors.

More Related Videos

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
In-vitro Mutagenesis01:16

In-vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...